title: Capecitabine, irinotecan (CAPIRI) and sunitinib in metastatic colorectal cancer.
authors.affiliation: Department of Medical Oncology, Radboud University Nijmegen Medical Center , Nijmegen , The Netherlands.
authors.forename: M J
authors.initials: MJ
authors.lastname: Boers-Sonderen
authors.forename: I M E
authors.initials: IM
authors.lastname: Desar
authors.forename: M
authors.initials: M
authors.lastname: Koopman
authors.forename: C J
authors.initials: CJ
authors.lastname: Punt
authors.forename: C M L
authors.initials: CM
authors.lastname: van Herpen
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D000069287:Capecitabine; D015331:Cohort Studies; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000556:secondary; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives; D005500:Follow-Up Studies; D006801:Humans; D007211:Indoles / Q000008:administration & dosage; D000077146:Irinotecan; D020714:Maximum Tolerated Dose; D011758:Pyrroles / Q000008:administration & dosage; D000077210:Sunitinib; D016896:Treatment Outcome
chemical_list: D007211:Indoles; D011758:Pyrroles; D003841:Deoxycytidine; D000069287:Capecitabine; D000077146:Irinotecan; D005472:Fluorouracil; D000077210:Sunitinib; D002166:Camptothecin